Leinco Technologies

Anti-Human CD15 - PE

Product Code:
 
LEI-C160
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgM
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
TG1
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Flow Cytometry
Shipping:
 
2-8°C
Storage:
 
This R-PE conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C160-50ug50 ug£170.00
Quantity:
LEI-C160-100ug100 ug£232.00
Quantity:
LEI-C160-200ug200 ug£333.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
The CD15 antigen is expressed on approximately 95% of human peripheral blood eosinophils and neutrophils and is present on approximately 20% of mature circulating monocytes. Anti-CD15 has virtually no reactivity with T or B cells.1,2,3
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
R-phycoerythrin (PE)
Format:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Long Description:
Anti-CD15-R-phycoerythrin may be used for enumerating mature granulocytes in peripheral blood.
NCBI Gene:
2526
Target:
CD15

References

1. Leukocyte Typing III (1987) Oxford University Press 2. Hogg, N. H. et al. (1984) Immunology 53:753 3. Linch D. C. et al. (1984) Blood 63:566 4. Beverley, P. C. L. et al. (1980) Nature 287:332